Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma
Abstract Background The 2-week schedule of hypofractionated radiotherapy as a salvage treatment for hepatocellular carcinoma (HCC) has previously exhibited promising results; this study aimed to assess its long-term clinical outcomes in patients with recurrent HCC ineligible for curative treatments....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-10-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-018-4953-x |
| _version_ | 1818275508152958976 |
|---|---|
| author | Jongmoo Park Jinhong Jung Daegeun Kim In-Hye Jung Jin-hong Park Jong Hoon Kim Sang-wook Lee Sang Min Yoon |
| author_facet | Jongmoo Park Jinhong Jung Daegeun Kim In-Hye Jung Jin-hong Park Jong Hoon Kim Sang-wook Lee Sang Min Yoon |
| author_sort | Jongmoo Park |
| collection | DOAJ |
| description | Abstract Background The 2-week schedule of hypofractionated radiotherapy as a salvage treatment for hepatocellular carcinoma (HCC) has previously exhibited promising results; this study aimed to assess its long-term clinical outcomes in patients with recurrent HCC ineligible for curative treatments. Methods We retrospectively enrolled 77 patients (84 lesions) with HCC who were treated with hypofractionated radiotherapy between December 2008 and July 2013. Primary inclusion criteria were HCC unsuitable for curative treatments and HCC located within 2 cm of a critical normal organ. We administered 3.5–5 Gy/fraction for 2 weeks, resulting in a total dose of 35–50 Gy. Results The median follow-up period was 33.6 (range, 4.8–78.3) months. The 3- and 5-year overall survival rates were 52.3% and 40.9%, respectively, and local control rates were 79.5% and 72.6% in all treated lesions, respectively. The 5-year local control rate was better in the higher radiation dose group than in the lower radiation dose group (50 Gy: 79.7% vs. < 50 Gy: 66.1%); however, the difference was not statistically significant (P = 0.493). We observed grade ≥ 3 hepatic toxicity in 2 (2.6%) patients and grade 3 gastrointestinal bleeding in 1 (1.3%) patient. However, grade ≥ 4 toxicity was not observed after hypofractionated radiotherapy. Conclusions The 2-week schedule of hypofractionated radiotherapy for recurrent HCC exhibited good local control and acceptable treatment-related toxicity during the long-term follow-up period. Thus, this fractionation schedule can be a potential salvage treatment option for recurrent HCC, particularly for tumors located close to a radiosensitive gastrointestinal organ. |
| first_indexed | 2024-12-12T22:30:52Z |
| format | Article |
| id | doaj.art-a0789e20bda14bf3952e9f80f6bd7a9b |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-12T22:30:52Z |
| publishDate | 2018-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-a0789e20bda14bf3952e9f80f6bd7a9b2022-12-22T00:09:36ZengBMCBMC Cancer1471-24072018-10-011811810.1186/s12885-018-4953-xLong-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinomaJongmoo Park0Jinhong Jung1Daegeun Kim2In-Hye Jung3Jin-hong Park4Jong Hoon Kim5Sang-wook Lee6Sang Min Yoon7Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of MedicineUniversity of Ulsan College of MedicineDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of MedicineDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of MedicineAbstract Background The 2-week schedule of hypofractionated radiotherapy as a salvage treatment for hepatocellular carcinoma (HCC) has previously exhibited promising results; this study aimed to assess its long-term clinical outcomes in patients with recurrent HCC ineligible for curative treatments. Methods We retrospectively enrolled 77 patients (84 lesions) with HCC who were treated with hypofractionated radiotherapy between December 2008 and July 2013. Primary inclusion criteria were HCC unsuitable for curative treatments and HCC located within 2 cm of a critical normal organ. We administered 3.5–5 Gy/fraction for 2 weeks, resulting in a total dose of 35–50 Gy. Results The median follow-up period was 33.6 (range, 4.8–78.3) months. The 3- and 5-year overall survival rates were 52.3% and 40.9%, respectively, and local control rates were 79.5% and 72.6% in all treated lesions, respectively. The 5-year local control rate was better in the higher radiation dose group than in the lower radiation dose group (50 Gy: 79.7% vs. < 50 Gy: 66.1%); however, the difference was not statistically significant (P = 0.493). We observed grade ≥ 3 hepatic toxicity in 2 (2.6%) patients and grade 3 gastrointestinal bleeding in 1 (1.3%) patient. However, grade ≥ 4 toxicity was not observed after hypofractionated radiotherapy. Conclusions The 2-week schedule of hypofractionated radiotherapy for recurrent HCC exhibited good local control and acceptable treatment-related toxicity during the long-term follow-up period. Thus, this fractionation schedule can be a potential salvage treatment option for recurrent HCC, particularly for tumors located close to a radiosensitive gastrointestinal organ.http://link.springer.com/article/10.1186/s12885-018-4953-xHepatocellular carcinomaHypofractionated radiotherapySalvage therapy |
| spellingShingle | Jongmoo Park Jinhong Jung Daegeun Kim In-Hye Jung Jin-hong Park Jong Hoon Kim Sang-wook Lee Sang Min Yoon Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma BMC Cancer Hepatocellular carcinoma Hypofractionated radiotherapy Salvage therapy |
| title | Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma |
| title_full | Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma |
| title_fullStr | Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma |
| title_full_unstemmed | Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma |
| title_short | Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma |
| title_sort | long term outcomes of the 2 week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma |
| topic | Hepatocellular carcinoma Hypofractionated radiotherapy Salvage therapy |
| url | http://link.springer.com/article/10.1186/s12885-018-4953-x |
| work_keys_str_mv | AT jongmoopark longtermoutcomesofthe2weekscheduleofhypofractionatedradiotherapyforrecurrenthepatocellularcarcinoma AT jinhongjung longtermoutcomesofthe2weekscheduleofhypofractionatedradiotherapyforrecurrenthepatocellularcarcinoma AT daegeunkim longtermoutcomesofthe2weekscheduleofhypofractionatedradiotherapyforrecurrenthepatocellularcarcinoma AT inhyejung longtermoutcomesofthe2weekscheduleofhypofractionatedradiotherapyforrecurrenthepatocellularcarcinoma AT jinhongpark longtermoutcomesofthe2weekscheduleofhypofractionatedradiotherapyforrecurrenthepatocellularcarcinoma AT jonghoonkim longtermoutcomesofthe2weekscheduleofhypofractionatedradiotherapyforrecurrenthepatocellularcarcinoma AT sangwooklee longtermoutcomesofthe2weekscheduleofhypofractionatedradiotherapyforrecurrenthepatocellularcarcinoma AT sangminyoon longtermoutcomesofthe2weekscheduleofhypofractionatedradiotherapyforrecurrenthepatocellularcarcinoma |